Sign in4 stories
The company disclosed Fast Track designation for its lead EGFR inhibitor and set an end-of-phase-1 FDA meeting for later in 2026, alongside cash from its August IPO.
SEC filing
The company presented updated Phase 1/2 SOLARA trial data at the IASLC 2026 World Conference on Lung Cancer, following recent FDA Fast Track designation for the drug.
SEC filing
The clinical-stage oncology company will sell 9,375,000 shares on Nasdaq under the ticker BLSM, with shares expected to begin trading around August 10, 2026.
SEC filing
The clinical-stage oncology company disclosed plans to list on Nasdaq, with lead programs in EGFR-mutant lung cancer and AML/MDS, alongside a $60.6 million 2025 net loss.
SEC filing